A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of a bioCSL Split Virion, Inactivated Influenza Vaccine in Healthy Volunteers Aged 18-60 Years

Trial Profile

A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of a bioCSL Split Virion, Inactivated Influenza Vaccine in Healthy Volunteers Aged 18-60 Years

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Influenza virus vaccine (Afluria) (Primary) ; Influenza virus vaccine (Afluria) (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors CSL
  • Most Recent Events

    • 08 Jun 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2013-001420-19).
    • 05 Jun 2013 New trial record
    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top